Answers are grounded in this paper and cite their sources.
The recurrence and metastasis of osteosarcoma after surgery and chemotherapy treatments are still a clinical challenge. Astragalus polysaccharide (APS) possesses notable antitumor activity but rather low bioavailability after intravenous or oral administration. Herein, a porous composite hydrogel combined with alginate (ALG) was prepared for the efficient local delivery of APS, which demonstrated a biphasic release profile with an initial burst release in the first several hours and a sustained release in the long term. The APS/ALG-Ca2+ gel exhibited antitumor activity, specifically enhancing the inhibition of cell proliferation with an inhibition rate of 97.85 ± 0.29% within 48 h, demonstrating cytotoxicity approximately equivalent to a 5-fold dose of APS solution. The promotion of apoptosis was also shown by the increased expression of cleaved caspase-3 by ∼11-fold in vivo. Concurrently, its inhibitory effect on cell migration was validated through a Transwell assay in vitro and metastatic foci in livers and lungs in vivo (with significantly decreased expression of platelet-derived growth factor D (PDGFD) and receptor beta (PDGFRB)). Furthermore, in mouse models, it demonstrated sustained suppression of osteosarcoma recurrence following B-cell maturation in the spleen. Our findings suggested that the APS/ALG-Ca2+ gel could be a feasible local adjuvant strategy of postsurgical osteosarcoma for further preclinical evaluation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: